[{"orgOrder":0,"company":"Syneos Health","sponsor":"Eloxx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ELX-02","moa":"80S Ribosome","graph1":"Nephrology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"5-grass Mix Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"EMA401","moa":"Angiotensin II type 2 (AT-2) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"EMA401","moa":"Angiotensin II type 2 (AT-2) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AZD0156","moa":"ATM serine\/threonine kinase (ATM)","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Philogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Bifikafusp Alfa","moa":"BCMA receptor\/Microtubule","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"11","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Lantheus Medical Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Prism Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PRI-724","moa":"CBP\/beta catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Prism Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PRI-724","moa":"CBP\/beta catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Prism Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PRI-724","moa":"CBP\/beta catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BT595","moa":"CD20","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BT595","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ALXN1820","moa":"Complement factor P (CFP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"Prostaglandin G\/H synthase 1; 3-hydroxy-3-methylglutaryl-coenzyme A reductase; Prostaglandin G\/H synthase 2; Aldo-keto reductase family 1 member C1; 5'-AMP-activated protein kinase; Endothelin-1 receptor; Cellular tumor antigen p53; Endoplasmic reticulum chaperone BiP; Ribosomal protein S6 kinase alpha-3; NF-kappa-B inhibitor alpha; Tumor necrosis factor-inducible gene 6 protein; Caspase-1; Caspase-3; Inhibitor of nuclear factor kappa-B kinase subunit beta; Extracellular signal-regulated kinase (ERK); G1\/S-specific cyclin-D1; Myc proto-oncogene protein; Proliferating cell nuclear antigen; Cyclin A; Sialidase-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Antares Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Antares Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Antares Pharma"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"1","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Galera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"GC4711","moa":"Dismutase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Appili Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"MGB Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Byondis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"DNA | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"enzyme inhibitors: inhibitors of histone deacetylase; vinca alkaloids","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Estetrol","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"11","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Udonitrectag","moa":"FGFR4","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor||FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor||FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Crossject","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Crossject"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2015","type":"Inapplicable","leadProduct":"SER-109","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Lantheus Medical Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Perflutren","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Debiopharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Debio 0932","moa":"HSP90","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GSK3640254","moa":"Human immunodeficiency virus Maturation (HIV Mat)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"CuraTeQ Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ CuraTeQ Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ CuraTeQ Biologics"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ALXN1830","moa":"IgG receptor FcRn large subunit p51","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Recordati","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Iodixanol","moa":"iodine-containing contrast media","graph1":"Nephrology","graph2":"Phase IV","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"11","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Shanghai SIMR Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SR419","moa":"Ion Channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Abcuro, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ABC008","moa":"Killer cell lectin-like receptor subfamily G member 1 (KLRG1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"9","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"MetrioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MP1032","moa":"Macrophage","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Neurim Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piromelatine","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"9","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"APL-1202","moa":"MetAP2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Asieris Pharmaceuticals"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bevenopran","moa":"Mu opioid receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Vyluma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"NVK-002","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"JHP Pharmaceuticals LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Purified Protein Derivative","moa":"Mycobacterial protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"EVP-6124","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Innate Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"MIS416","moa":"NOD2\/TLR9","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ALO-02","moa":"Opioid receptor (OPR)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Trevi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Trevi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Syneos Health \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Syneos Health \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ARGENTINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Holy Stone Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Odyssey Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Agreement","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Syneos Health \/ Odyssey Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Odyssey Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Synermore Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SYN023","moa":"Rabies virus glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Galera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"DSP-0337","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Daxibotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Daxibotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Oncolys BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"OBP-301","moa":"Telomerase reverse transcriptase (TERT)","graph1":"Oncology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Oncolys BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Oncolys BioPharma"},{"orgOrder":0,"company":"Syneos Health","sponsor":"FivepHusion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"DSP-0509","moa":"TLR7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"JHP Pharmaceuticals LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Tuberculin PPD","moa":"Toll-like receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"JHP Pharmaceuticals LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Aplisol","moa":"Tuberculin PPD","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"162","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ACH-000029","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aiolos Bio","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Aiolos Bio","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Aiolos Bio"},{"orgOrder":0,"company":"Syneos Health","sponsor":"AprilBio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"APB-R3","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ AprilBio","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ AprilBio"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Cat-Pad","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Creative Medical Technology","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Partnership","leadProduct":"CELZ-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Creative Medical Technology","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Creative Medical Technology"},{"orgOrder":0,"company":"Syneos Health","sponsor":"US Specialty Formulations, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CoV2-OGEN1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Syneos Health \/ US Specialty Formulations, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ US Specialty Formulations, LLC"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GATT-Patch","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"1","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"GeneScience Pharmaceuticals Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GS1-144","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Medicago","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"H5 VLP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Himuka AM Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HM201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Himuka AM Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Himuka AM Pharma"},{"orgOrder":0,"company":"Syneos Health","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Stallergenes Greer","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Levocept","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Shanghai Novamab Biopharmaceuticals Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LQ036","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Shanghai Novamab Biopharmaceuticals Co. Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Shanghai Novamab Biopharmaceuticals Co. Ltd."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Liminal BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PBI-4547","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Que Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Q-122","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Chengdu Kanghua Biological Products","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Norovirus Hexavalent Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Chengdu Kanghua Biological Products","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Chengdu Kanghua Biological Products"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"RPh201","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SB206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SB206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"F-star Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"SB9200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ F-star Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ F-star Therapeutics"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SLC-391","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"SynerK Pharmatech (Suzhou) Limited","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SNK-396","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ SynerK Pharmatech (Suzhou) Limited","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ SynerK Pharmatech (Suzhou) Limited"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SOV2012-F1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SOV2012-F1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SUN13837","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Tsumura & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TU-100","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"TV-46763","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VB0004","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Veracept","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Veracept","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"DS-5565","moa":"Voltage-gated calcium channel alpha2\/delta subunit 1 | Voltage-gated calcium channel alpha2\/delta subunit 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"DS-5565","moa":"Voltage-gated calcium channel alpha2\/delta subunit 1 | Voltage-gated calcium channel alpha2\/delta subunit 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"DS-5565","moa":"Voltage-gated calcium channel alpha2\/delta subunit 1 | Voltage-gated calcium channel alpha2\/delta subunit 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"DS-5565","moa":"Voltage-gated calcium channel alpha2\/delta subunit 1 | Voltage-gated calcium channel alpha2\/delta subunit 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Kamada","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Cryoport Systems Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"3","companyTruncated":"Syneos Health \/ Syneos Health"}]
Find Clinical Drug Pipeline Developments & Deals by Syneos Health
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target